Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I.

Saved in:
Bibliographic Details
Title: Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I.
Authors: Unger JM; SWOG Statistics and Data Management Center, Seattle, WA, USA.; Fred Hutchinson Cancer Center, Seattle, WA, USA., Qian L; SWOG Statistics and Data Management Center, Seattle, WA, USA.; Fred Hutchinson Cancer Center, Seattle, WA, USA., Redman MW; SWOG Statistics and Data Management Center, Seattle, WA, USA.; Fred Hutchinson Cancer Center, Seattle, WA, USA., Tavernier SS; Idaho State University, Pocatello, ID, USA., Minasian L; Division of Cancer Prevention, National Cancer Institute, Community Oncology and Prevention Trials Group, Rockville, MD, USA., Sigal EV; Friends of Cancer Research, Washington, DC, USA., Papadimitrakopoulou VA; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Pfizer Oncology, Inc, New York, NY, USA., Leblanc M; SWOG Statistics and Data Management Center, Seattle, WA, USA.; Fred Hutchinson Cancer Center, Seattle, WA, USA., Cleeland CS; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dzingle SA; SWOG Data Operations Center, Cancer Research and Biostatistics, Seattle, WA, USA., Summers TJ; Cookeville Regional Medical Center, Southeast NCORP, Cookeville, TN, USA., Chao H; Veterans Affairs Connecticut Healthcare System, Yale University School of Medicine, Massachusetts Veterans Epidemiology Research and Information Center, New Haven, CT, USA., Madhusudhana S; University Health Truman Medical Center, University of Kansas Cancer Center-Midwest Cancer Alliance Rural MU National Cancer Institute Community Oncology Research Program, Kansas City, MO, USA., Villaruz L; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA., Crawford J; Duke Cancer Institute, Durham, NC, USA., Gray JE; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Kelly KL; University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA., Gandara DR; University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA., Bazhenova L; University of California San Diego Moores Cancer Center, La Jolla, CA, USA., Herbst RS; Yale Cancer Center, New Haven, CT, USA., Gettinger SN; Yale Cancer Center, New Haven, CT, USA., Moinpour CM; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Source: Journal of the National Cancer Institute [J Natl Cancer Inst] 2023 Apr 11; Vol. 115 (4), pp. 437-446.
Publication Type: Clinical Trial, Phase III; Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info: Publisher: Oxford University Press Country of Publication: United States NLM ID: 7503089 Publication Model: Print Cited Medium: Internet ISSN: 1460-2105 (Electronic) Linking ISSN: 00278874 NLM ISO Abbreviation: J Natl Cancer Inst Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1460-2105
DOI:10.1093/jnci/djad003